Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 31, Issue 4, 2006, Pages 265-270

  Li, Wei ^a,b,d   Gao, Jun ^b   Zhao, Hong Zhi ^a   Liu, Chang Xiao ^a,c  

^a TIANJIN UNIVERSITY   (China)

^b Tianjin Tasly Group Co Ltd   (China)

^c State Key Laboratories of Pharmacodynamics and Pharmacokinetics   (China)

^d TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH   (China)

Author keywords

Human; Liquid chromatography (HPLC); Pharmacokinetic; Silybin; Silybin phosphatidylcholine complex

Indexed keywords

PHOSPHATIDYLCHOLINE; SILIBININ;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; QUANTITATIVE ANALYSIS; SINGLE DRUG DOSE; ULTRAVIOLET RADIATION;

EID: 33846969208     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190466     Document Type: Article

References (15)

1. Flora K, Hahn M, Rosen H, Benner K(1998) : Milk thistle (Silybum marianum) for the therapy of liver diseases. Am J Gastroenterol, 93, 139-143.
2. Valenzuela A, Garrido A(1994) : Biochemical bases of the pharmacological action of the flavonoid silymarin and its structural isomersilybinin. Biol Res, 27, 105-112.
3. Morazzoni P, Bombardelli E(1995) : Silybum marianum (Carduus marianus). Fitoterapia, 66, 3-42.
4. Skottova N, Krecman V(1998) : Dietary silymarin improves removal of low density lipoproteins by the perfused rat liver. Acta Univ Palacki Olomuc (Olomouc) Fac Med, 141, 39-40.
5. Skottova N, Krecman V, Simanek V(1999) : Activities of silymarin and its flavonolignans upon low density lipoprotein oxidizability in vitro. Phytother Res, 13, 535-537.
6. Barzaghi N, Crema F, Gatti G, Perucca E(1990) : Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Euro. J. Drug. Metab. Pharmacokinet., 15, 333-338.
7. Morazzoni P, Magistretti MJ, Giachetti C, Zanolo G(1992) : Comparative bioavailability of silipide, a new flavanolignan complex, in rats. Euro. J. Drug. Metab. Pharmacokinet., 17, 39-44.
8. Morazzoni P, Montalbetti A, Malandrino S, Pifferi G(1993) : Comparative pharmacokinetics of silipide and silymarin in rats. Euro. J. Drug. Metab. Pharmacokinet., 18, 289-297.
9. Marisa C, Salvatore M, Maria JM(1992) : Protective activity of silipide on liver damage in rodents. Japan J. Pharmacol., 60, 315-321.
10. Nina S, Zdenek S, Rostislav V, Karel U, Alexander J, Vilim S(2001) : Pharmacokinetic study of iodine-labeled silybinins in rat. Pharmacological Research, 44, 247-253.
11. Gibaldi M, Perrier D(1982) : Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 409-417.
12. Cavallini L, Lucchetti G(1976) : Cinsiderazioni clinicofarmacologiche sulla silimarina. Gazz. Med. It, 135, 365-374.
13. Schandalik R, Gatti G, Perucca EP(1992) : harmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung, 42, 964-968.
14. Schandalik R, Gatti G, Perucca E(1994) : Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs Exp Clin Res, 20, 37-42.
15. Lorenz D, Lucker PW, Mennicke WH, Wetzelaberger N(1984) : Pharmacokinetic studies with silymarin in human serum and bile. Meth. Find. Exp. Clin. Pharmacol., 6, 655-661.